Portfolio News Immunome

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

By WebmasterFebruary 6, 2024December 12th, 2024No Comments

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile

Previous PostUnite Us and Ride Health Partner to Improve Access to Transportation Services for New Yorkers
Next Post"Sean Lyden MD, Professor and Chairman Vascular Surgery Cleveland Clinic on the mainstage at ISET 2024"